SEC Company Response from Mosaic ImmunoEngineering Inc. (CPMV) (CIK 0000836564) (CPMV) — Jan 25, 2021
Mosaic ImmunoEngineering Inc. (CPMV) (CIK 0000836564)
Date: Jan. 25, 2021 · CIK: 0000836564 · Accession: 0001683168-21-000250
AI Filing Summary & Sentiment
File numbers found in text: 333-251261
Show Raw Text
CORRESP
1
filename1.htm
January 25, 2021
VIA EDGAR
Mr. David Gessert
Mr. Tim Buchmiller
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Re:
Mosaic ImmunoEngineering Inc.
Amendment No. 1 to Registration Statement on Form S-3/A
File No. 333-251261
Dear Messrs. Gessert and Buchmiller:
Mosaic ImmunoEngineering
Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form
S-3/A be accelerated so that it will become effective at 4:00 p.m. Eastern time on January 29, 2021, or as soon thereafter as practicable.
This letter constitutes
the Company’s confirmation of its awareness of its obligations under the Act.
Please telephone the
undersigned at (657) 208-0890 or Dean Colucci of Duane Morris LLP at (973) 424-2020 if you have any questions with respect to the
foregoing.
Very truly yours,
Mosaic ImmunoEngineering Inc.
By:
/s/ Steven King
Name:
Steven King
Title:
President and Chief Executive Officer
cc:
Dean M. Colucci, Esq.
Duane Morris LLP
1537
S. Novato Blvd, Novato CA 94947
www.mosaicie.com
| info@mosaicie.com